Diffuse Large B Cell Lymphoma Clinical Trials in Houston, Texas

7 studies are recruiting for diffuse large b cell lymphoma in Houston, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

   Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL)/Burkitt lymphoma, or neuroblastom…

   Stage

   Phase 1

   Ages

   0 to 25

   Site

   University of Texas MD Anderson Cancer Center ( Site 1007), Houston, Texas

   Locations

   71 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06395103 on ClinicalTrials.gov

2. A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

   The purpose of this study is to evaluate if zilovertamab vedotin with standard treatment can help people live longer without the cancer growing or spreading than people who receive standard treatment alone.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Houston Methodist Cancer Center ( Site 0154), Houston, Texas

   Locations

   275 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06717347 on ClinicalTrials.gov

3. A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

   Study consists of two main parts to explore tacabrutideg recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Md Anderson Cancer Center, Houston, Texas

   Locations

   115 in total

   Run by

   BeOne Medicines

   See if you can join NCT05006716 on ClinicalTrials.gov

4. Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

   This is a Phase 1/2, first-in-human, open-label, dose-escalating trial designed to assess the safety and efficacy of VNX-101 in patients with relapsed or refractory CD19-positive hematologic malignancies.

   Stage

   Phase 1

   Ages

   13 to 90

   Site

   University of Texas MD Anderson Cancer Center, Houston, Texas

   Locations

   11 in total

   Run by

   Vironexis Biotherapeutics Inc.

   See if you can join NCT06533579 on ClinicalTrials.gov

5. A Long-term Extension Study of PCI-32765 (Ibrutinib)

   The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been completed according to the parent protocol, are actively rece…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   MD Anderson Cancer Center - University of Texas, Houston, Texas

   Locations

   175 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT01804686 on ClinicalTrials.gov

6. Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

   The use of venetoclax-based therapies for pediatric patients with relapsed or refractory malignancies is increasingly common outside of the clinical trial setting. For patients who cannot swallow tablets, it is common to crush the tablets and dissolve them in liquid to create a solution. However, n…

   Stage

   Not phased

   Ages

   0 to 38

   Site

   Texas Children's Hospital, Houston, Texas

   Locations

   5 in total

   Run by

   Children's Hospital Medical Center, Cincinnati

   See if you can join NCT06131801 on ClinicalTrials.gov

7. A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.

   A phase 1, multicenter, open label, non-randomized dose escalation and dose expansion study to examine the maximum tolerated dose, (MTD), minimum effective dose (MED) and/or recommended dose for expansion (RDE) of intratumoral ONM-501 as monotherapy and in combination with a PD-1 checkpoint inhibit…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   MD Anderson Cancer Center, Houston, Texas

   Locations

   16 in total

   Run by

   OncoNano Medicine, Inc.

   See if you can join NCT06022029 on ClinicalTrials.gov